Skip to content

Clinical study of brain-specific cmiRNA markers combined with ABCD3-I score for precise management of transient ischemic attack and mild stroke

Clinical study of brain-specific cmiRNA markers combined with ABCD3-I score for precise management of transient ischemic attack and mild stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040008
Enrollment
Unknown
Registered
2020-11-18
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebrovascular disease

Interventions

Gold Standard:clinical symptoms and brain MRI
cmiRNA

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. It conforms to the diagnostic criteria of TIA formulated by the fourth National Conference on Cerebrovascular Epidemiology; 2. The onset of the disease is sudden, and the symptoms and signs of focal neurological impairment or defect appear rapidly. The symptoms and signs completely disappear within 24 h; 3. No specific acute cerebral infarction lesion corresponding to neurological impairment was confirmed by cranial MRI or (and)CT examination; 4. Onset of TIA within 7 days; 5. Informed consent is signed by the patient or family member.

Exclusion criteria

Exclusion criteria: 1. A head CT or MRI diagnosis is bleeding or other pathologic brain disorder, such as vascular malformation, tumor, abscess, or other common nonischemic brain disease (such as multiple sclerosis); 2. Associated with partial epileptic seizures, Meniere's disease, metabolic diseases (hypoglycemia, hypercalcemia), migraine with aura, glaucoma and other diseases; 3. Patients or family members refuse to sign informed consent. There are only separate sensory symptoms (such as numbness), separate changes in vision, and separate dizziness or vertigo.

Design outcomes

Primary

MeasureTime frame
serum mi-RNA;

Countries

China

Contacts

Public ContactWang Yang

Shenzhen Second People's Hospital

helenwy1978@163.com+86 18922898155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026